Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,796.00
(
0.00%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.00
(
3.21%
)
Bitcoin
69,811.47
(
-2.01%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: DewDiligence post# 162166

Thursday, 06/06/2013 9:33:17 AM

Thursday, June 06, 2013 9:33:17 AM

Post# of 257257
UBS likes the risk/reward profile for Momenta Pharmaceuticals (MNTA +4%) as analyst Ami Fadi says management's rhetoric indicates approval for generic Copaxone may come in time for 2015 patent expirations. The shares are upgraded to Buy from Neutral (price target to $17 from $13). For a detailed discussion of the MNTA vs. Teva Copaxone story, see SA contributor Jon Crowley's recent article.
http://m.seekingalpha.com/article/1453781-why-momenta-offers-a-unique-opportunity-in-the-pharmaceutical-industry
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today